This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mascola, J. R.
Right arrow Articles by Robb, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mascola, J. R.
Right arrow Articles by Robb, M. L.

 Previous Article  |  Next Article 

J. Virol., Oct 1997, 7198-7206, Vol 71, No. 10
Copyright © 1997, American Society for Microbiology

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12

JR Mascola, MK Louder, TC VanCott, CV Sapan, JS Lambert, LR Muenz, B Bunow, DL Birx and ML Robb
Walter Reed Army Institute of Research and Department of Infectious Diseases, Naval Medical Research Institute, Rockville, Maryland 20850, USA. jmascola@pasteur.hjf.org

Three antibody reagents that neutralize primary human immunodeficiency virus type 1 (HIV-1) isolates were tested for magnitude and breadth of neutralization when used alone or in double or triple combinations. Hyperimmune anti-HIV immunoglobulin (HIVIG) is derived from the plasma of HIV-1-infected donors, and monoclonal antibodies (MAbs) 2F5 and 2G12 bind to distinct regions of the HIV-1 envelope glycoprotein. The antibodies were initially tested against a panel of 15 clade B HIV-1 isolates, using a single concentration that is achievable in vivo (HIVIG, 2,500 microg/ml; MAbs, 25 microg/ml). Individual antibody reagents neutralized many of the viruses tested, but antibody potency varied substantially among the viruses. The virus neutralization produced by double combinations of HIVIG plus 2F5 or 2G12, the two MAbs together, or the triple combination of HIVIG, 2F5, and 2G12 was generally equal to or greater than that predicted by the effect of individual antibodies. Overall, the triple combination displayed the greatest magnitude and breadth of neutralization. Synergistic neutralization was evaluated by analyzing data from dose-response curves of each individual antibody reagent compared to the triple combination and was demonstrated against each of four viruses tested. Therefore, combinations of polyclonal and monoclonal anti-HIV antibodies can produce additive or synergistic neutralization of primary HIV-1 isolates. Passive immunotherapy for treatment or prophylaxis of HIV-1 should consider mixtures of potent neutralizing antibody reagents to expand the magnitude and breadth of virus neutralization.


This article has been cited by other articles:

  • Arnold, G. F., Velasco, P. K., Holmes, A. K., Wrin, T., Geisler, S. C., Phung, P., Tian, Y., Resnick, D. A., Ma, X., Mariano, T. M., Petropoulos, C. J., Taylor, J. W., Katinger, H., Arnold, E. (2009). Broad Neutralization of Human Immunodeficiency Virus Type 1 (HIV-1) Elicited from Human Rhinoviruses That Display the HIV-1 gp41 ELDKWA Epitope. J. Virol. 83: 5087-5100 [Abstract] [Full Text]  
  • Wright, A., Lamm, M. E., Huang, Y. T. (2008). Excretion of Human Immunodeficiency Virus Type 1 through Polarized Epithelium by Immunoglobulin A. J. Virol. 82: 11526-11535 [Abstract] [Full Text]  
  • Duval, M., Posner, M. R., Cavacini, L. A. (2008). A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils. J. Virol. 82: 4671-4674 [Abstract] [Full Text]  
  • Manrique, A., Rusert, P., Joos, B., Fischer, M., Kuster, H., Leemann, C., Niederost, B., Weber, R., Stiegler, G., Katinger, H., Gunthard, H. F., Trkola, A. (2007). In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10. J. Virol. 81: 8793-8808 [Abstract] [Full Text]  
  • Bublil, E. M., Yeger-Azuz, S., Gershoni, J. M. (2006). Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120. FASEB J. 20: 1762-1774 [Abstract] [Full Text]  
  • Coley, A. M., Parisi, K., Masciantonio, R., Hoeck, J., Casey, J. L., Murphy, V. J., Harris, K. S., Batchelor, A. H., Anders, R. F., Foley, M. (2006). The Most Polymorphic Residue on Plasmodium falciparum Apical Membrane Antigen 1 Determines Binding of an Invasion-Inhibitory Antibody. Infect. Immun. 74: 2628-2636 [Abstract] [Full Text]  
  • Forsell, M. N. E., Li, Y., Sundback, M., Svehla, K., Liljestrom, P., Mascola, J. R., Wyatt, R., Hedestam, G. B. K. (2005). Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus. J. Virol. 79: 10902-10914 [Abstract] [Full Text]  
  • Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., Bilska, M., Kothe, D. L., Salazar-Gonzalez, J. F., Wei, X., Decker, J. M., Hahn, B. H., Montefiori, D. C. (2005). Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. J. Virol. 79: 10108-10125 [Abstract] [Full Text]  
  • Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., Petropoulos, C. J., Burton, D. R. (2004). Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. J. Virol. 78: 13232-13252 [Abstract] [Full Text]  
  • Trujillo, J. D., Kumpula-McWhirter, N. M., Hotzel, K. J., Gonzalez, M., Cheevers, W. P. (2004). Glycosylation of Immunodominant Linear Epitopes in the Carboxy-Terminal Region of the Caprine Arthritis-Encephalitis Virus Surface Envelope Enhances Vaccine-Induced Type-Specific and Cross-Reactive Neutralizing Antibody Responses. J. Virol. 78: 9190-9202 [Abstract] [Full Text]  
  • Zhang, H., Huang, Y., Fayad, R., Spear, G. T., Qiao, L. (2004). Induction of Mucosal and Systemic Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 (HIV-1) by Oral Immunization with Bovine Papillomavirus-HIV-1 gp41 Chimeric Virus-Like Particles. J. Virol. 78: 8342-8348 [Abstract] [Full Text]  
  • Haigwood, N. L., Montefiori, D. C., Sutton, W. F., McClure, J., Watson, A. J., Voss, G., Hirsch, V. M., Richardson, B. A., Letvin, N. L., Hu, S.-L., Johnson, P. R. (2004). Passive Immunotherapy in Simian Immunodeficiency Virus-Infected Macaques Accelerates the Development of Neutralizing Antibodies. J. Virol. 78: 5983-5995 [Abstract] [Full Text]  
  • Lorin, C., Mollet, L., Delebecque, F., Combredet, C., Hurtrel, B., Charneau, P., Brahic, M., Tangy, F. (2004). A Single Injection of Recombinant Measles Virus Vaccines Expressing Human Immunodeficiency Virus (HIV) Type 1 Clade B Envelope Glycoproteins Induces Neutralizing Antibodies and Cellular Immune Responses to HIV. J. Virol. 78: 146-157 [Abstract] [Full Text]  
  • Wolbank, S., Kunert, R., Stiegler, G., Katinger, H. (2003). Characterization of Human Class-Switched Polymeric (Immunoglobulin M [IgM] and IgA) Anti-Human Immunodeficiency Virus Type 1 Antibodies 2F5 and 2G12. J. Virol. 77: 4095-4103 [Abstract] [Full Text]  
  • Mascola, J. R., Louder, M. K., Winter, C., Prabhakara, R., De Rosa, S. C., Douek, D. C., Hill, B. J., Gabuzda, D., Roederer, M. (2002). Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells. J. Virol. 76: 4810-4821 [Abstract] [Full Text]  
  • Bures, R., Morris, L., Williamson, C., Ramjee, G., Deers, M., Fiscus, S. A., Abdool-Karim, S., Montefiori, D. C. (2002). Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa. J. Virol. 76: 2233-2244 [Abstract] [Full Text]  
  • Zwick, M. B., Wang, M., Poignard, P., Stiegler, G., Katinger, H., Burton, D. R., Parren, P. W. H. I. (2001). Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies. J. Virol. 75: 12198-12208 [Abstract] [Full Text]  
  • Verrier, F., Nadas, A., Gorny, M. K., Zolla-Pazner, S. (2001). Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6. J. Virol. 75: 9177-9186 [Abstract] [Full Text]  
  • Scharf, O., Golding, H., King, L. R., Eller, N., Frazier, D., Golding, B., Scott, D. E. (2001). Immunoglobulin G3 from Polyclonal Human Immunodeficiency Virus (HIV) Immune Globulin Is More Potent than Other Subclasses in Neutralizing HIV Type 1. J. Virol. 75: 6558-6565 [Abstract] [Full Text]  
  • Montefiori, D. C., Safrit, J. T., Lydy, S. L., Barry, A. P., Bilska, M., Vo, H. T. T., Klein, M., Tartaglia, J., Robinson, H. L., Rovinski, B. (2001). Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus Macaques. J. Virol. 75: 5879-5890 [Abstract] [Full Text]  
  • Nyambi, P. N., Nadas, A., Mbah, H. A., Burda, S., Williams, C., Gorny, M. K., Zolla-Pazner, S. (2000). Immunoreactivity of Intact Virions of Human Immunodeficiency Virus Type 1 (HIV-1) Reveals the Existence of Fewer HIV-1 Immunotypes than Genotypes. J. Virol. 74: 10670-10680 [Abstract] [Full Text]  
  • Glamann, J., Hirsch, V. M. (2000). Characterization of a Macaque Recombinant Monoclonal Antibody That Binds to a CD4-Induced Epitope and Neutralizes Simian Immunodeficiency Virus. J. Virol. 74: 7158-7163 [Abstract] [Full Text]  
  • Scala, G., Chen, X., Liu, W., Telles, J. N., Cohen, O. J., Vaccarezza, M., Igarashi, T., Fauci, A. S. (1999). Selection of HIV-Specific Immunogenic Epitopes by Screening Random Peptide Libraries with HIV-1-Positive Sera. J. Immunol. 162: 6155-6161 [Abstract] [Full Text]  
  • Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., Lu, Y., Robb, M. L., Katinger, H., Birx, D. L. (1999). Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies. J. Virol. 73: 4009-4018 [Abstract] [Full Text]  
  • Stamatos, N. M., Mascola, J. R., Kalyanaraman, V. S., Louder, M. K., Frampton, L. M., Birx, D. L., VanCott, T. C. (1998). Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140. J. Virol. 72: 9656-9667 [Abstract] [Full Text]  
  • Frankel, S. S., Steinman, R. M., Michael, N. L., Kim, S. R., Bhardwaj, N., Pope, M., Louder, M. K., Ehrenberg, P. K., Parren, P. W. H. I., Burton, D. R., Katinger, H., VanCott, T. C., Robb, M. L., Birx, D. L., Mascola, J. R. (1998). Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells. J. Virol. 72: 9788-9794 [Abstract] [Full Text]  
  • Parren, P. W. H. I., Wang, M., Trkola, A., Binley, J. M., Purtscher, M., Katinger, H., Moore, J. P., Burton, D. R. (1998). Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1. J. Virol. 72: 10270-10274 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»